var data={"title":"Clarithromycin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clarithromycin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5913?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clarithromycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clarithromycin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Clarithromycin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51130805\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Clarithromycin Safety Alert</span>\n      <span class=\"collapsible-date\">February 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is advising caution regarding the use of clarithromycin in patients with heart disease because of a potential increased risk of heart problems or death that can occur years later. This is based on a review of the results of a 10-year follow-up study (CLARICOR), which observed an unexpected increase in deaths among patients with coronary heart disease who received a 2-week course of clarithromycin; the increase in deaths became apparent after patients had been followed for 1 year or longer. There is no clear explanation for how clarithromycin would lead to more deaths than placebo; however, the FDA has added a new warning about this increased risk and information about the study results to the clarithromycin drug labeling.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is urging providers to weigh the benefits and risks of clarithromycin before prescribing it to any patient, even for short periods and particularly for patients with heart disease, and to consider using other available antibiotics. Providers should advise patients with heart disease of the signs and symptoms of cardiovascular problems, regardless of the medical condition for which the patient is being treated with clarithromycin.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Further information can be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm597862.htm&amp;token=VD2DLhrxMMrk855/F8AHnlsaD3v9ylPUWCbV5fhPQP49irBrsXN6rdVpdTTMKGGiAGxjPnSwhUbj2KnBs82SS2XSwzyA7f5eoAKTqY1zRWUPX/uUB+/76BwamMYO1qzZ9bI9ivb+vMj9W/Ad2oJ4Cg==&amp;TOPIC_ID=9273\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm597862.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152372\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Biaxin XL Pac [DSC];</li>\n      <li>Biaxin XL [DSC];</li>\n      <li>Biaxin [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152373\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Accel-Clarithromycin;</li>\n      <li>Apo-Clarithromycin;</li>\n      <li>Apo-Clarithromycin XL;</li>\n      <li>Biaxin;</li>\n      <li>Biaxin BID;</li>\n      <li>Biaxin XL;</li>\n      <li>Dom-Clarithromycin;</li>\n      <li>Mylan-Clarithromycin;</li>\n      <li>PMS-Clarithromycin;</li>\n      <li>RAN-Clarithromycin;</li>\n      <li>Riva-Clarithromycin;</li>\n      <li>Sandoz-Clarithromycin;</li>\n      <li>Teva-Clarithromycin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152420\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Macrolide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152377\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> Oral: 250 to 500 mg every 12 hours <b>or</b> 1000 mg (two 500 mg extended-release tablets) once daily for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchitis, acute bacterial exacerbation:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>M. catarrhalis</i> and <i>S. pneumoniae</i>: 250 mg every 12 hours for 7 to 14 days <b>or</b> 1,000 mg (two 500 mg extended-release tablets) once daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>H. influenzae</i>: 500 mg every 12 hours for 7 to 14 days <b>or</b> 1,000 mg (two 500 mg extended-release tablets) once daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>H. parainfluenzae</i>: 500 mg every 12 hours for 7 days <b>or</b> 1,000 mg (two 500 mg extended-release tablets) once daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bartonellosis in HIV-infected patients (excluding CNS infections and endocarditis) (off-label use; HHS [OI adult 2015]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment (alternative to preferred): 500 mg twice daily for at least 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Long-term suppressive therapy: 500 mg twice daily; may discontinue if completed 3 to 4 months therapy and CD4 &gt;200 cells/mm<sup>3</sup> for at least 6 months. <b>Note: </b>Some clinicians would discontinue only if Bartonella titers have also decreased four-fold</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>H. pylori </i>eradication</b>: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">American College of Gastroenterology guidelines (Chey 2007; Chey 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Clarithromycin triple therapy</i>: 500 mg twice daily, in combination with a standard-dose or double-dose proton pump inhibitor, and either amoxicillin 1 g twice daily or metronidazole 500 mg three times daily; continue regimen for 14 days. <b>Note:</b> Avoid use of clarithromycin triple therapy in patients with risk factors for macrolide resistance (eg, prior macrolide exposure, local clarithromycin resistance rates &ge;15%, eradication rates with clarithromycin-based regimens &le;85%) (ACG [Chey 2017]; Fallone 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Concomitant regimen</i>: 500 mg twice daily in combination with amoxicillin 1 g twice daily, and a standard-dose proton pump inhibitor twice daily, and either metronidazole or tinidazole 500 mg twice daily; continue treatment for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Sequential regimen</i>: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 5 to 7 days; then follow with clarithromycin 500 mg twice daily, and a standard-dose proton pump inhibitor twice daily, and either metronidazole or tinidazole 500 mg twice daily for 5 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hybrid regimen</i>: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 7 days; then follow with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, a standard-dose PPI twice daily, and either metronidazole or tinidazole 500 mg twice daily for 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (off-label use):</b> Oral: 500 mg twice daily for 14 to 21 days (not recommended for pregnant women) (Wormser 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mycobacterial infection, disseminated (prophylaxis and treatment):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: 500 mg twice daily (use with other antimycobacterial drugs, eg, ethambutol or rifampin). Continue therapy if clinical response is observed; may discontinue when patient is considered at low risk of disseminated infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: <i>Mycobacterium avium</i> complex disease (MAC) in HIV-infected patients (HHS [OI adult 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Primary prophylaxis (patients with CD4 count &lt;50 cells/mm<sup>3</sup>):</i> 500 mg twice daily; may discontinue when CD4 count &gt;100 cells/mm<sup>3</sup> for &ge;3 months in response to ART.<b> Note:</b> If effective ART is initiated immediately and viral suppression is achieved, some experts do not recommend routine initiation of MAC primary prophylaxis, regardless of initial CD4 count (IAS-USA [Gunthard 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment and chronic maintenance therapy:</i> 500 mg twice daily plus ethambutol; consider additional agents (eg, rifabutin, aminoglycoside, fluoroquinolone) for CD4 &lt;50 cells/mm<sup>3</sup>, high mycobacterial load, or ineffective antiretroviral therapy; may discontinue chronic maintenance if no signs/symptoms of MAC disease, have maintained a CD4 count &gt;100 cells/mm<sup>3</sup> for &gt;6 months in response to ART, and completed at least 12 months of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pertussis (off-label use):</b> Oral: 500 mg twice daily for 7 days (CDC 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis, tonsillitis (alternative agent):</b> Oral: 250 mg every 12 hours for 10 days (IDSA [Shulman 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>C. pneumoniae</i>, <i>M. pneumoniae</i>, and <i>S. pneumoniae</i>: 250 mg every 12 hours for 7 to 14 days <b>or</b> 1,000 mg (two 500 mg extended-release tablets) once daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>H. influenzae</i>: 250 mg every 12 hours for 7 days <b>or</b> 1,000 mg (two 500 mg extended-release tablets) once daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>H. parainfluenzae</i> and <i>M. catarrhalis</i>: 1000 mg (two 500 mg extended-release tablets) once daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Outpatient empiric therapy: 500 mg twice daily for 5 days, in combination with a beta-lactam (Lim 2009; Mandell 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against infective endocarditis (off-label use):</b> Oral: 500 mg 30 to 60 minutes prior to procedure. <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA (Wilson 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sinusitis:</b> Oral: 500 mg every 12 hours for 14 days <b>or</b> 1,000 mg (two 500 mg extended-release tablets) once daily for 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infection, uncomplicated:</b> Oral: 250 mg every 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for concomitant therapy:</b> Atazanavir: Decrease clarithromycin dose by 50%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152399\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Clarithromycin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range: Note:</b> All pediatric dosing recommendations based on immediate release product formulations (tablet and oral suspension):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;6 months, Children, and Adolescents: Oral: 7.5 mg/kg every 12 hours (maximum: 500 mg/dose) for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bartonellosis in (treatment/long-term suppressive therapy) HIV-infected patients (excluding CNS infections and endocarditis) (off-label use):</b> Adolescents: Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (off-label use):</b> Infants, Children, and Adolescents: Oral: 7.5 mg/kg/dose (maximum dose: 500 mg) twice daily for 14-21 days (Wormser 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mycobacterial infection, disseminated (prevention and treatment):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: 7.5 mg/kg/dose (maximum: 500 mg/dose) twice daily; use in combination with other antimycobacterial agents for the treatment of disseminated MAC. <b>Note:</b> Safety of clarithromycin for MAC not studied in children &lt;20 months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternative recommendations: Disseminated <i>Mycobacterium avium</i> complex (MAC) disease in HIV-exposed/-positive patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and children (CDC 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Primary prophylaxis: </i> 7.5 mg/kg/dose (maximum: 500 mg/dose) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Secondary prophylaxis:</i> 7.5 mg/kg/dose (maximum: 500 mg/dose) twice daily, plus ethambutol, with or without rifabutin</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment:</i> 7.5-15 mg/kg/dose (maximum: 500 mg/dose) twice daily plus ethambutol, plus rifabutin (for severe disease)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otitis media: </b> Infants &ge;6 months, Children, and Adolescents: Oral: 7.5 mg/kg/dose (maximum: 500 mg/dose) every 12 hours for 10 days. <b>Note:</b> Due to increased <i>S. pneumoniae</i> and <i>H. influenzae</i> resistance, macrolides are not routinely recommended as a treatment option (Lieberthal 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pertussis (off-label use):</b> Infants &ge;1 month, Children, and Adolescents: Oral: 7.5 mg/kg/dose (maximum: 500 mg/dose) every 12 hours for 7 days (CDC 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis/tonsillitis (alternative agent):</b> Oral: 7.5 mg/kg/dose (maximum: 250 mg/dose) every 12 hours for 10 days (IDSA [Shulman 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired:</b> Infants &gt;3 months and Children: Oral: <b>Note:</b> A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Presumed atypical <i>(M. pneumoniae, C. pneumoniae, C. trachomatis)</i> infection, mild-to-severe atypical infection or step-down therapy (alternative to azithromycin): 7.5 mg/kg/dose (maximum dose: 500 mg) every 12 hours (Bradley 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against infective endocarditis (off-label use):</b> Children and Adolescents: Oral: 15 mg/kg/dose (maximum: 500 mg/dose) 30-60 minutes before procedure (maximum: 500 mg). <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA (Wilson 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sinusitis:</b> Infants &ge;6 months, Children, and Adolescents: Oral: 7.5 mg/kg/dose (maximum: 500 mg/dose) every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin/skin structure infections, uncomplicated:</b> Infants &ge;6 months, Children, and Adolescents: Oral: 7.5 mg/kg/dose (maximum: 250 mg dose) every 12 hours for 10 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152378\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152379\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &lt;30 mL/minute: Decrease clarithromycin dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemodialysis:  Administer after HD session is completed (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">In combination with atazanavir or ritonavir: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 30 to 60 mL/minute: Decrease clarithromycin  dose by 50%. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;30 mL/minute: Decrease clarithromycin dose by 75%. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152380\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary if renal function is normal; however, in patients with hepatic impairment and concomitant severe renal impairment, a dosage reduction or prolonged dosing intervals may be appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152345\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Biaxin: 250 mg/5 mL (50 mL [DSC], 100 mL [DSC]) [fruit punch flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (50 mL, 100 mL); 250 mg/5 mL (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Biaxin: 250 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Biaxin: 500 mg [DSC] [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Biaxin XL: 500 mg [DSC] [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Biaxin XL Pac: 500 mg [DSC] [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152331\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152349\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release tablets and granules for suspension: Administer with or without meals. Administer every 12 hours rather than twice daily to avoid peak and trough variation. Shake suspension well before each use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablets: Administer with food. Do not break, crush, or chew.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152348\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchitis, acute bacterial exacerbation: </b>Treatment of acute bacterial exacerbation of chronic bronchitis in adults due to susceptible <i>Haemophilus </i><i> influenzae</i>, <i>H. </i><i>parainfluenzae</i>, <i>Moraxella</i> <i>catarrhalis</i>, or <i>Streptococcus</i><i> pneumoniae.</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Helicobacter pylori</i> eradication:</b> Eradication of <i>Helicobacter pylori</i> to reduce the risk of duodenal ulcer recurrence as a component of combination therapy (triple therapy) in adults with <i>H. pylori</i> infection and duodenal ulcer disease (active or 5 year history of duodenal ulcer).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Regimens that contain clarithromycin as the single antibacterial agent are more likely to be associated with the development of clarithromycin resistance. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin-resistant isolates (efficacy is reduced).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mycobacterial infections, disseminated:</b> Prophylaxis and treatment of disseminated mycobacterial infections due to <i>Mycobacterium avium</i> complex (MAC) in patients with advanced HIV infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otitis media:</b> Treatment of acute otitis media in pediatric patients due to susceptible <i>H. influenzae</i>, <i>M.</i><i> catarrhalis</i>, or <i>S. pneumoniae.</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis/tonsillitis:</b> Treatment of pharyngitis/tonsillitis due to susceptible <i>Streptococcus pyogenes </i>(alternative agent).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired:</b> Treatment of community-acquired pneumonia due to susceptible <i>Mycoplasma pneumoniae</i>, <i>S. pneumoniae</i>, or <i>Chlamydophila pneumoniae </i>(adult and pediatric patients) and<i> H. influenzae, H. parainfluenzae, </i>or<i> M. catarrhalis </i>(adults)<i>.</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sinusitis:</b> Treatment of acute maxillary sinusitis due to susceptible <i>H. influenzae, S. pneumoniae,</i> or <i>M. catarrhalis.</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin/skin structure infections:</b> Treatment of uncomplicated skin/skin structure infection due to susceptible <i>Staphylococcus aureus</i> or <i>S. pyogenes.</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26122358\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bartonellosis infection (treatment/long-term suppressive therapy) in HIV-infected patients (adolescents and adults); Infective endocarditis (prophylaxis); Lyme disease; Pertussis; Pneumonia, community acquired (children)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152427\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Clarithromycin may be confused with Claritin, clindamycin, erythromycin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152338\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (2%), insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (children 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (adults 3% to 7%), vomiting (children 6%), diarrhea (3% to 6%), nausea (adults 3%), abdominal pain (2% to 3%), dyspepsia (adults 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Prolonged prothrombin time (adults 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylactoid reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis (including oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distension, abnormal albumin-globulin ratio, acne vulgaris, acute generalized exanthematous pustulosis, ageusia, agranulocytosis, altered sense of smell, anaphylaxis, angioedema, anorexia, anosmia, anxiety, asthma, atrial fibrillation, behavioral changes, bullous dermatitis, cellulitis, chest pain, chills, cholestasis, cholestatic hepatitis, <i>Clostridium difficile</i> associated diarrhea, <i>Clostridium difficile</i> (colitis), confusion, constipation, dark urine (abnormal urine color associated with liver injury), decreased appetite, decreased white blood cell count, dental discoloration (reversible with dental cleaning), depersonalization, depression, disorientation, dizziness, DRESS syndrome, drowsiness, dyskinesia, eosinophilia, epistaxis, eructation, esophagitis, extrasystoles, fatigue, fever, flatulence, gastritis, gastroenteritis, gastroesophageal reflux disease, glossitis, hallucination, hearing loss (reversible), hemorrhage, hepatic failure, hepatic insufficiency, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hyperhidrosis, hypersensitivity reaction, hypoglycemia, IgA vasculitis, increased gamma-glutamyl transferase, increased INR, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum creatinine, infection, interstitial nephritis, jaundice, leukopenia, loss of consciousness, maculopapular rash, malaise, manic behavior, muscle spasm, myalgia, myopathy, neck stiffness, nervousness, neutropenia, nightmares, palpitations, pancreatitis, parasomnias, paresthesia, prolonged QT interval on ECG, pruritus, pseudomembranous colitis, psychosis, pulmonary embolism, rectal pain, renal failure, rhabdomyolysis, seizure, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, tinnitus, tongue discoloration, torsades de pointes, toxic epidermal necrolysis, tremor, urticaria, vaginal infection, ventricular arrhythmia, ventricular tachycardia, vertigo, weakness, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152352\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to clarithromycin, erythromycin, any of the macrolide antibiotics, or any component of the formulation; history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin; concomitant use with cisapride, pimozide, ergot alkaloids (eg, ergotamine, dihydroergotamine),  or HMG-CoA reductase inhibitors extensively metabolized by CYP3A4 (eg, lovastatin, simvastatin); concomitant use with colchicine in patients with renal or hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Severe hepatic failure in combination with renal impairment; history of QT prolongation (congenital or documented acquired QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes; hypokalemia; concomitant use with saquinavir, midazolam (oral), colchicine (regardless of hepatic/renal impairment), ticagrelor; concomitant use with astemizole, terfenadine, or ranolazine (not available in Canada)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152335\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: Use has been associated with QT prolongation and infrequent cases of arrhythmias, including torsades de pointes (may be fatal); avoid use in patients with known prolongation of the QT interval, ventricular cardiac arrhythmia (including torsades de pointes), uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and patients receiving Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents or other drugs known to prolong the QT interval.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Elevated liver function tests and hepatitis (hepatocellular and/or cholestatic with or without jaundice) have been reported; usually reversible after discontinuation of clarithromycin. May lead to hepatic failure or death (rarely), especially in the presence of preexisting diseases and/or concomitant use of medications. Discontinue immediately if symptoms of hepatitis (eg, anorexia, jaundice, abdominal tenderness, pruritus, dark urine) occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe acute reactions have been reported, including anaphylaxis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Sch&ouml;nlein purpura (IgA vasculitis), and acute generalized exanthematous pustulosis; discontinue therapy and initiate treatment immediately for severe acute hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CAD: Use with caution in patients with CAD. A clinical trial in patients with CAD demonstrated an increase in risk of all-cause mortality &ge;1 year after the end of treatment in patients randomized to receive clarithromycin. Other epidemiologic studies evaluating this risk have variable results.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms and new onset of symptoms has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in severe renal impairment; dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; elderly patients may be at increased risk of torsades de pointes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV patients: Decreased survival has been observed in HIV patients with <i>Mycobacterium avium</i> complex (MAC) receiving clarithromycin doses above the maximum recommended dose; maximum recommended dosing should not be exceeded in this population. Development of resistance to clarithromycin has been observed when used as prophylaxis and treatment of MAC infection (Biaxin Canadian product labeling 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended release formulation: The presence of extended release tablets in the stool has been reported, particularly in patients with anatomic (eg, ileostomy, colostomy) or functional GI disorders with decreased transit times. Consider alternative dosage forms (eg, suspension) or an alternative antimicrobial for patients with tablet residue in the stool and no signs of clinical improvement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Helicobacter pylori</i> eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. Current guidelines recommend 10 to 14 days of therapy (triple or quadruple) for eradication of <i>H. pylori</i> in pediatric and adult patients (Chey 2007; NASPHGAN [Koletzko 2011]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152413\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (strong), P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152340\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9273&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Abemaciclib.  Management: In patients taking abemaciclib at a dose of 200 mg or 150 mg twice daily, reduce the dose to 100 mg twice daily when combined with strong CYP3A4 inhibitors. In patients taking abemaciclib 100 mg twice daily, decrease the dose to 50 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer the P-gp inhibitor simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alitretinoin (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic).  Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP3A4 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ALPRAZolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ALPRAZolam.  Management: Consider using an alternative agent that is less likely to interact. If combined, monitor for increased therapeutic/toxic effects of alprazolam if combined with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Clarithromycin. Management: Avoid clarithromycin doses greater than 1000 mg/day when used with an antihepaciviral combination product. Further dose reductions may be needed in patients with impaired renal function. Consider an alternative antimicrobial for any non-MAC infection.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antineoplastic Agents (Vinca Alkaloids): Macrolide Antibiotics may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues.  Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Clarithromycin may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Please refer to the full interaction monograph for details concerning the recommended dose adjustments.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Astemizole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Clarithromycin may increase the serum concentration of AtorvaSTATin.  Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin.  If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barnidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Barnidipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betrixaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban.  Management: Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bictegravir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine.  Management: Consider alternatives when possible; bilastine should be avoided in patients with moderate to severe renal insufficiency who are receiving p-glycoprotein inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Blonanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: Clarithromycin may increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Clarithromycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May increase serum concentrations of the active metabolite(s) of Clarithromycin. Specifically, bosentan may increase concentrations of 14-hydroxyclarithromycin. Bosentan may decrease the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Bosentan. Management: Consider alternative antimicrobial if possible. The clinical activity of clarithromycin may be altered, and increased bosentan toxicity may be expected.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole.  Management: Reduce brexpiprazole dose to 50% of usual with a strong CYP3A4 inhibitor; reduce to 25% of usual if used with both a moderate CYP3A4 inhibitor and a CYP2D6 inhibitor, or if a strong CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with strong CYP3A4 inhibitors when possible. If combination cannot be avoided, reduce the brigatinib dose by approximately 50%, rounding to the nearest tablet strength (ie, from 180 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bromocriptine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Topical).  Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of BusPIRone.  Management: Limit the buspirone dose to 2.5 mg daily and monitor patients for increased buspirone effects/toxicities if combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabazitaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.  Management: Concurrent use of cabazitaxel with strong inhibitors of CYP3A4 should be avoided when possible.  If such a combination must be used, consider a 25% reduction in the cabazitaxel dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabergoline: Clarithromycin may increase the serum concentration of Cabergoline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.  Management: Avoid use of a strong CYP3A4 inhibitor with cabozantinib if possible. If combined, cabozantinib dose adjustments are recommended and vary based on the cabozantinib product used and the indication for use. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcifediol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.  Management: Consider using a noninteracting macrolide.  Felodipine Canadian labeling specifically recommends avoiding its use in combination with clarithromycin.<b> Exceptions: </b>Clevidipine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabidiol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabidiol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Clarithromycin. Management: Consider alternatives to this combination when possible. If combined, monitor for increased carbamazepine effects/toxicities and for reduced clarithromycin efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cariprazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cariprazine.  Management: Cariprazine dose reductions of 50% are required; specific recommended management varies slightly for those stable on cariprazine versus those just starting cariprazine.  See prescribing information or full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib.  Management:  If such combinations cannot be avoided, the ceritinib dose should be reduced by approximately one-third (to the nearest 150 mg).  Resume the prior ceritinib dose after cessation of the strong CYP3A4 inhibitor.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving strong inhibitors of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Macrolide Antibiotics may enhance the QTc-prolonging effect of Cisapride. Macrolide Antibiotics may decrease the metabolism of Cisapride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: Clarithromycin may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Clarithromycin.  Management: Consider alternative antibiotics. Reduce clarithromycin dose by 50% in patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir with estimated creatinine clearance 50 to 60 mL/min. Closely monitor for clarithromycin toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Copanlisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Copanlisib.  Management: If concomitant use of copanlisib and strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg. Monitor patients for increased copanlisib effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Orally inhaled fluticasone propionate with a strong CYP3A4 inhibitor is not recommended.<b> Exceptions: </b>Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Systemic). <b> Exceptions: </b>MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Clarithromycin may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin. Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and impair its efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin. Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and may impair clarithromycin efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inhibitors): CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Alitretinoin (Systemic); AmLODIPine; Benzhydrocodone; Buprenorphine; Gefitinib; HYDROcodone; Praziquantel; Telithromycin; Vinorelbine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Clarithromycin may increase the serum concentration of Dabigatran Etexilate.  Management: Dose reductions and/or avoidance of this combination may be necessary. Specific recommendations vary by international labeling, renal function, and indication for dabigatran. Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dabrafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Daclatasvir.  Management: Decrease the daclatasvir dose to 30 mg once daily if combined with a strong CYP3A4 inhibitor.  No dose adjustment is needed when daclatasvir is used with darunavir/cobicistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.  Management: This combination should be avoided; consider reducing dasatinib dose if a strong CYP3A4 inhibitor must be used. If using dasatinib 70 mg/day or 100 mg/day, consider reduction to 20 mg/day; if using dasatinib 140 mg/day, consider reduction to 40 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Delamanid.  Management: Increase electrocardiogram (ECG) monitoring frequency if delamanid is combined with strong CYP3A4 inhibitors because the risk for QTc interval prolongation may be increased. Continue frequent ECG assessments throughout the full delamanid treatment period.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Ophthalmic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dexamethasone (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dihydroergotamine: Clarithromycin may increase the serum concentration of Dihydroergotamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: Clarithromycin may enhance the hypoglycemic effect of Disopyramide. Clarithromycin may enhance the QTc-prolonging effect of Disopyramide. Clarithromycin may increase the serum concentration of Disopyramide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOCEtaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOCEtaxel.  Management: Avoid the concomitant use of docetaxel and strong CYP3A4 inhibitors when possible. If combined use is unavoidable, consider a 50% docetaxel dose reduction and monitor for increased docetaxel toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Domperidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to strong CYP3A4 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to P-glycoprotein inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban.  Management: See full monograph for details. Reduced doses are recommended for patients receiving edoxaban for venous thromboembolism in combination with certain inhibitors. Similar dose adjustment is not recommended for edoxaban use in atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Clarithromycin. Management: Consider using an alternative antibiotic, such as azithromycin, for patients taking efavirenz. If concomitant therapy cannot be avoided, monitor for decreased therapeutic effect of clarithromycin and increased incidence of skin rash.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eletriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Macrolide Antibiotics may increase the serum concentration of Ergot Derivatives. Cabergoline and Clarithromycin may interact, see specific monograph for full details. <b> Exceptions: </b>Cabergoline; Nicergoline; Pergolide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergotamine: Clarithromycin may increase the serum concentration of Ergotamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.  Management: Avoid use of this combination when possible.  When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estazolam: Macrolide Antibiotics may increase the serum concentration of Estazolam.  Management: Consider an alternative less likely to interact. Azithromycin is likely a lower-risk macrolide, and benzodiazepines less dependent on CYP3A metabolism (e.g., lorazepam, oxazepam) are similarly less likely to interact.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eszopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eszopiclone.  Management: Limit the eszopiclone dose to 2 mg daily when combined with strong CYP3A4 inhibitors and monitor for increased eszopiclone effects and toxicities (eg, somnolence, drowsiness, CNS depression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etizolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Etizolam.  Management: Consider use of lower etizolam doses when using this combination; specific recommendations concerning dose adjustment are not available.  Monitor clinical response to the combination closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of Macrolide Antibiotics. Clarithromycin AUC is reduced and levels of the active metabolite (14-hydroxy-clarithromycin) are modestly increased. Management: For the treatment of <i>Mycobacterium avium</i> complex, consider changing to alternative agent, such as azithromycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Evogliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: Clarithromycin may enhance the QTc-prolonging effect of FLUoxetine. Clarithromycin may increase the serum concentration of FLUoxetine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).  Management: Use of orally inhaled fluticasone propionate with strong CYP3A4 inhibitors is not recommended.  Use of orally inhaled fluticasone furoate with strong CYP3A4 inhibitors should be done with caution.  Monitor patients using such a combination more closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GlipiZIDE: Clarithromycin may increase the serum concentration of GlipiZIDE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GlyBURIDE: Clarithromycin may increase the serum concentration of GlyBURIDE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of HydrOXYzine.  Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ibrutinib.  Management: Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term (eg, anti-infectives for 7 days or less), interrupt ibrutinib therapy until the strong CYP3A4 inhibitor is discontinued.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imidafenacin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imidafenacin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irinotecan Products: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Strong) may increase isavuconazole serum concentrations.  Management: Combined use is considered contraindicated per US labeling. Lopinavir/ritonavir (and possibly other uses of ritonavir doses less than 400 mg every 12 hours) is treated as a possible exception to this contraindication despite strongly inhibiting CYP3A4.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full monograph content for specific age- and weight-based recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib adult dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lercanidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levobupivacaine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levomilnacipran: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.  Management: Do not exceed a maximum adult levomilnacipran dose of 80 mg/day in patients also receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: Clarithromycin may enhance the QTc-prolonging effect of Lopinavir. Lopinavir may diminish the therapeutic effect of Clarithromycin. Specifically, lopinavir may decrease the formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness. Lopinavir may increase the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Lopinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: Clarithromycin may increase the serum concentration of Lovastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macitentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inhibitors. If combined, monitor closely for increased manidipine effects and toxicities. Manidipine dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MedroxyPROGESTERone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MedroxyPROGESTERone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose reduction in patients receiving strong CYP3A4 inhibitors and monitor for increased steroid related adverse effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam: Macrolide Antibiotics may increase the serum concentration of Midazolam.  Management: Consider an alternative less likely to interact. Azithromycin is likely a lower-risk macrolide, and benzodiazepines less dependent on CYP3A metabolism (e.g., lorazepam, oxazepam) are similarly less likely to interact.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midostaurin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Midostaurin.  Management: Seek alternatives to the concomitant use of midostaurin and strong CYP3A4 inhibitors if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirodenafil.  Management: Consider using a lower dose of mirodenafil when used with strong CYP3A4 inhibitors. Monitor for increased mirodenafil effects/toxicities with the use of this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: Macrolide Antibiotics may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalfurafine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Combined Inhibitors of CYP3A4 and P-glycoprotein may increase the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Olaparib.  Management: Avoid use of strong CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxybutynin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Palbociclib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.  Management: Reduce the panobinostat dose to 10 mg when it must be used with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parecoxib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Parecoxib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PARoxetine: Clarithromycin may enhance the adverse/toxic effect of PARoxetine. Clarithromycin may enhance the QTc-prolonging effect of PARoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piperaquine: CYP3A4 Inhibitors (Strong) may enhance the QTc-prolonging effect of Piperaquine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Piperaquine.  Management: Avoid the concomitant use of piperaquine and strong CYP3A4 inhibitors when possible. If this combination cannot be avoided, frequent ECG monitoring is recommended due to the increased risk for QTc prolongation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitavastatin: Clarithromycin may increase the serum concentration of Pitavastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PONATinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.  Management: Per ponatinib U.S. prescribing information, the adult starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pranlukast: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pravastatin: Clarithromycin may increase the serum concentration of Pravastatin.  Management: Limit pravastatin to a maximum of 40 mg/day (for adults) when used in combination with clarithromycin.  If this combination is used, monitor patients more closely for evidence of pravastatin toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Praziquantel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PrednisoLONE (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed. Clarithromycin may increase the serum concentration of Protease Inhibitors. Management: Avoid clarithromycin adult doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QUEtiapine: Clarithromycin may enhance the QTc-prolonging effect of QUEtiapine. Clarithromycin may increase the serum concentration of QUEtiapine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Radotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Radotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Reboxetine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Repaglinide.  Management: The addition of a CYP2C8 inhibitor to this drug combination may substantially increase the magnitude of increase in repaglinide exposure.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retapamulin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.  Management: Avoid this combination in patients less than 2 years old.  No action is required in other populations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: Macrolide Antibiotics may decrease the metabolism of Rifamycin Derivatives. <b> Exceptions: </b>Rifapentine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Macrolide Antibiotics may increase the serum concentration of Rilpivirine.  Management: Consider the use of azithromycin or another non-macrolide alternative when appropriate to avoid this potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Clarithromycin may increase the serum concentration of Rivaroxaban.  Management: In patients with impaired renal function, clarithromycin should not be used unless the potential benefits outweigh the potential risks. This interaction is unlikely clinically significant in patients with normal renal function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rupatadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: This combination should be avoided under some circumstances. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil: Clarithromycin may increase the serum concentration of Sildenafil. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Clarithromycin may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sirolimus.  Management: Consider avoiding concurrent use of sirolimus with strong CYP3A4 inhibitors in order to minimize the risk for sirolimus toxicity. Concomitant use of sirolimus and voriconazole or posaconazole is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUFentanil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SUFentanil.  Management: If a strong CYP3A4 inhibitor is initiated in a patient on sufentanil, consider a sufentanil dose reduction and monitor for increased sufentanil effects and toxicities (eg, respiratory depression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tacrolimus (Systemic).  Management: Monitor clinical tacrolimus response closely and frequently monitor tacrolimus serum concentrations with concurrent use of any strong CYP3A4 inhibitor.  Tacrolimus dose reductions and/or prolongation of the dosing interval will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tasimelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: Clarithromycin may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Clarithromycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Temsirolimus.  Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inhibitors whenever possible. If combined, decrease temsirolimus dose to 12.5 mg per week and monitor patients for increased temsirolimus effects and toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terfenadine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tezacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tezacaftor.  Management: When combined with strong CYP3A4 inhibitors, tezacaftor/ivacaftor (100 mg/150 mg) should be administered in the morning, twice a week, approximately 3 to 4 days apart. No evening doses of ivacaftor (150 mg) alone should be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Macrolide Antibiotics may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended adult dose of tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraZODone: May enhance the QTc-prolonging effect of Clarithromycin. Clarithromycin may increase the serum concentration of TraZODone. Management: Consider an alternative to this combination whenever possible. If combined, use a lower trazodone dose and monitor for increased effects of trazodone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Triazolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triazolam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Udenafil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.  Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combo should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Valbenazine.  Management: Reduce the valbenazine dose to 40 mg daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vardenafil: Clarithromycin may increase the serum concentration of Vardenafil.  Management: Recommendations regarding the concomitant use of vardenafil with clarithromycin vary between international labelings and between commercially available vardenafil brand name products (Levitra, Staxyn). Consult appropriate product labelings.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Venetoclax.  Management: These combinations are contraindicated during venetoclax initiation and ramp-up. In patients receiving steady venetoclax doses after completing ramp-up, reduce the venetoclax by at least 75% if strong CYP3A4 inhibitor use cannot be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg daily in patients receiving strong CYP3A4 inhibitors. The original vilazodone dose can be resumed following discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Clarithromycin may enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine.  Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.  Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity if these agents are combined.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152368\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Immediate release: Food delays rate, but not extent of absorption; Extended release: Food increases clarithromycin AUC by ~30% relative to fasting conditions. Management: Administer immediate release products without regard to meals. Administer extended release products with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152342\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152355\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been documented in some animal reproduction studies. Clarithromycin crosses the placenta (Witt 2003). The manufacturer recommends that clarithromycin not be used in a pregnant woman unless there are no alternative therapies. Clarithromycin is not recommended as a first-line agent for the treatment or prophylaxis of <i>Mycobacterium avium</i> complex or for treatment of bacterial respiratory disease in HIV-infected pregnant patients (HHS [OI adult 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152356\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Clarithromycin and its active metabolite (14-hydroxy clarithromycin) are excreted into breast milk. The manufacturer recommends that caution be used if administered to nursing women. Decreased appetite, diarrhea, rash, and somnolence have been noted in nursing infants exposed to macrolide antibiotics (Goldstein 2009). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6699915\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">BUN, creatinine; perform culture and sensitivity studies prior to initiating drug therapy as appropriate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152334\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Exerts its antibacterial action by binding to 50S ribosomal subunit resulting in inhibition of protein synthesis. The 14-OH metabolite of clarithromycin is twice as active as the parent compound against certain organisms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152351\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Rapid; food delays rate, but not extent of absorption</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release: Fasting is associated with ~30% lower AUC relative to administration with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Widely into most body tissues; manufacturer reports no data in regards to CNS penetration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 42% to 70% (Peters, 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Partially hepatic via CYP3A4; converted to 14-OH clarithromycin (active metabolite); undergoes extensive first-pass metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Immediate release: Clarithromycin: 3-7 hours; 14-OH-clarithromycin: 5-9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Immediate release: 2-3 hours; Extended release: 5-8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (20% to 40% as unchanged drug; additional 10% to 15% as metabolite); feces (29% to 40% mostly as metabolites) (Ferrero 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Approximates normal GFR</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152354\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Clarithromycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (50 mL): $66.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (50 mL): $97.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Clarithromycin ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $300.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Clarithromycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (60): $360.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $360.92</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152358\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abbotic (ID);</li>\n      <li>Abbotic Granule (ID);</li>\n      <li>Abbotic XL (ID);</li>\n      <li>Adel (MX);</li>\n      <li>Aeroxina (AR);</li>\n      <li>Avexus (HK, MY);</li>\n      <li>Aziclar (ET);</li>\n      <li>Azyklar (UA);</li>\n      <li>Baclecin (HK);</li>\n      <li>Bacterfin (EC);</li>\n      <li>Biaxin HP (DE);</li>\n      <li>Biclar (BE, LU);</li>\n      <li>Bicrolid (ID, LK, SG);</li>\n      <li>Binoclar (CR, DO, GT, HN, NI, PA, SV, VN);</li>\n      <li>Bysclas (PH);</li>\n      <li>C-Clarin (KR);</li>\n      <li>Carimycin (TW);</li>\n      <li>Clabet (PH);</li>\n      <li>Clacee (ZW);</li>\n      <li>Clacina (TH);</li>\n      <li>Clafax (LK);</li>\n      <li>Clamise (VN);</li>\n      <li>Clamisin (KR);</li>\n      <li>Clamycin (AE, BH, KW, LB, PH, QA, SA);</li>\n      <li>Clarac (AU, NZ);</li>\n      <li>Claranta (PH, ZW);</li>\n      <li>Clarem (ET);</li>\n      <li>Clarexid (HR);</li>\n      <li>Clari (SG);</li>\n      <li>Claribax (PH);</li>\n      <li>Claribid (IN);</li>\n      <li>Claricide (ET);</li>\n      <li>Claricin (BD);</li>\n      <li>Claricin-P (TH);</li>\n      <li>Claridar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Clarimac (IN, QA);</li>\n      <li>Clarimax (CL, CU);</li>\n      <li>Clarimed (PE);</li>\n      <li>Clarimin (LK);</li>\n      <li>Clarin (BD);</li>\n      <li>Clarion (LK);</li>\n      <li>Claripen (SG);</li>\n      <li>Clariston (EC);</li>\n      <li>Claritek (VN);</li>\n      <li>Clarith (JP, TH);</li>\n      <li>Clarithro (AU);</li>\n      <li>Clariva (QA);</li>\n      <li>Clariwin (SG);</li>\n      <li>Clarix (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Claroma (KR);</li>\n      <li>Claron (TH);</li>\n      <li>Clarosin (KR);</li>\n      <li>Clasine (PE);</li>\n      <li>Claxin (KR);</li>\n      <li>Cleron (SG, TR);</li>\n      <li>Clonocid (IE);</li>\n      <li>Clormicin (CO);</li>\n      <li>Clorom (IE);</li>\n      <li>Crixan OD (PH);</li>\n      <li>Fascar (TH);</li>\n      <li>Fromilid (HR, HU, MT, RO, TR);</li>\n      <li>Gervaken (MX);</li>\n      <li>Hecobac (ID);</li>\n      <li>Heliclar (LU);</li>\n      <li>Heliclo (KR);</li>\n      <li>Kalixocin (AU);</li>\n      <li>Klabax (ZW);</li>\n      <li>Klacid (AE, AT, AU, BG, BH, CH, CN, CY, CZ, DE, DK, EE, EG, ES, FI, HK, HU, IE, IL, IQ, IR, IS, IT, JO, KR, KW, LB, LT, LV, LY, MT, MY, NO, NZ, OM, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SY, TH, TR, VN, YE, ZW);</li>\n      <li>Klacid MR (MY, VN);</li>\n      <li>Klacid XL (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE, ZW);</li>\n      <li>Klafar (UA);</li>\n      <li>Klaribac (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Klaricid (AR, BB, BM, BR, BS, BZ, CL, CO, CR, DO, EC, GB, GR, GT, GY, HN, JM, KR, LK, MT, MX, NI, NL, PA, PE, PH, PK, PR, PY, SR, SV, TT, TW, UY, VE);</li>\n      <li>Klaricid Pediatric (PH);</li>\n      <li>Klaricid XL (KR);</li>\n      <li>Klarid (PH);</li>\n      <li>Klaridex (IL);</li>\n      <li>Klariger (IE);</li>\n      <li>Klarin (IL);</li>\n      <li>Klaris (KR);</li>\n      <li>Klarith (TW);</li>\n      <li>Klarithan (ZA);</li>\n      <li>Klarix (BD);</li>\n      <li>Klarmyn (MX, PH);</li>\n      <li>Klatsyd (UA);</li>\n      <li>Klerimed (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SG, SY, YE);</li>\n      <li>Klerimid (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Kofron (ES);</li>\n      <li>Krobicin (MX);</li>\n      <li>Macladin (IT);</li>\n      <li>Maclar (LU);</li>\n      <li>Macrodin (PH);</li>\n      <li>Mavid (DE);</li>\n      <li>Minatev (IE);</li>\n      <li>Monoclarium (SG);</li>\n      <li>Mononaxy (FR);</li>\n      <li>Naxy (FR);</li>\n      <li>Neo-Clarosip (MX);</li>\n      <li>Onexid (PH);</li>\n      <li>Orixal (ID);</li>\n      <li>Orokin (VN);</li>\n      <li>Resclar (ET);</li>\n      <li>Rolicytin (MX);</li>\n      <li>Suclari (KR);</li>\n      <li>Synclar (HK);</li>\n      <li>Veclam (IT);</li>\n      <li>Zeclar (FR);</li>\n      <li>Zix (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ADA Division of Legal Affairs, &ldquo;A Legal Perspective on Antibiotic Prophylaxis,&rdquo; <i>J Am Dent Assoc</i>, 2003, 134(9):1260.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/14529001 /pubmed\" target=\"_blank\" id=\"14529001 \">14529001 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association Council on Scientific Affairs, &ldquo;Combating Antibiotic Resistance,&rdquo; <i>J Am Dent Assoc</i>, 2004, 135(4):484-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/15127872 /pubmed\" target=\"_blank\" id=\"15127872 \">15127872 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society, &ldquo;Guidelines for the Initial Management of Adults With Community-Acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy,&rdquo; <i>Am Rev Respir Dis</i>, 1993, 148(5):1418-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8239186/pubmed\" target=\"_blank\" id=\"8239186\">8239186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsden GW, &ldquo;Erythromycin, Clarithromycin, and Azithromycin: Are the Differences Real?&rdquo; <i>Clin Ther</i>, 1996, 18(1):56-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8851453 /pubmed\" target=\"_blank\" id=\"8851453 \">8851453 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aspin MM, Hoberman A, McCarty J, et al, &ldquo;Comparative Study of the Safety and Efficacy of Clarithromycin and Amoxicillin-Clavulanate in the Treatment of Acute Otitis Media in Children,&rdquo; <i>J Pediatr</i>, 1994, 125(1):136-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8021763/pubmed\" target=\"_blank\" id=\"8021763\">8021763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barradell LB, Plosker GL, and McTavish D, &ldquo;Clarithromycin. A Review of Its Pharmacological Properties and Therapeutic Use in <i>Mycobacterium avium-intracellulare</i> Complex Infection in Patients With Acquired Immune Deficiency Syndrome,&rdquo; <i>Drugs</i>, 1993, 46(2):289-312.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/7691518/pubmed\" target=\"_blank\" id=\"7691518\">7691518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biaxin (clarithromycin) [prescribing information]. North Chicago, IL: AbbVie; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biaxin (clarithromycin) [product monograph]. Etobieoke, Ontario, Canada: BGP Pharma ULC; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonow RO, Carabello B, de Leon Jr, AC, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease),&rdquo; <i>J Am Coll Cardiol</i>, 1998, 32(5):1486-1588.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/9809971/pubmed\" target=\"_blank\" id=\"9809971\">9809971</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i> 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. <i>MMWR Recomm Rep</i>. 2009;58(RR-11):1-166. Available at <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/28071659/pubmed\" target=\"_blank\" id=\"28071659\">28071659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,&rdquo; <i>Am J Gastroenterol</i>, 2007 102(8):1808-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chu SY, Wilson DS, Guay DR, et al, &ldquo;Clarithromycin Pharmacokinetics in Healthy Young and Elderly Volunteers,&rdquo; <i>J Clin Pharmacol</i>, 1992, 32(11):1045-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/1474166/pubmed\" target=\"_blank\" id=\"1474166\">1474166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dajani AS, Taubert KA, Wilson W, et al, &ldquo;Prevention of Bacterial Endocarditis Recommendations by the American Heart Association,&rdquo; <i>JAMA</i> 1997, 277(22):1794-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/9178793/pubmed\" target=\"_blank\" id=\"9178793\">9178793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/27102658/pubmed\" target=\"_blank\" id=\"27102658\">27102658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferrero JL, Bopp BA, Marsh KC, et al. Metabolism and Disposition of Clarithromycin in Man. <i>Drug Metab Dispos</i>. 1990;18(4):441-446.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/1976065/pubmed\" target=\"_blank\" id=\"1976065\">1976065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldman MP and Longworth DL, &ldquo;The Role of Azithromycin and Clarithromycin in Clinical Practice,&rdquo; <i>Cleve Clin J Med</i>, 1993, 60(5):359-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8403355/pubmed\" target=\"_blank\" id=\"8403355\">8403355</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein LH, Berlin M, Tsur L, et al, &quot;The Safety of Macrolides During Lactation,&quot; <i>Breastfeed Med</i>, 2009, 4(4):197-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/19366316/pubmed\" target=\"_blank\" id=\"19366316\">19366316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guay DR, &ldquo;Pharmacokinetics of New Macrolides,&rdquo; <i>Infect Med</i>, 1992, 9(Suppl A):9-13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guay DR and Craft JC, &ldquo;Overview of the Pharmacology of Clarithromycin Suspension in Children and a Comparison With That in Adults,&rdquo; <i>Pediatr Infect Dis J</i>, 1993, 12(12 Suppl 3):106-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8295810/pubmed\" target=\"_blank\" id=\"8295810\">8295810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    G&uuml;nthard HF, Saag MS, Benson CA,et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. <i>JAMA</i>. 2016;316(2):191-210.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/27404187/pubmed\" target=\"_blank\" id=\"27404187\">27404187</a>]</span><span class=\"doi\">10.1001/jama.2016.8900</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed June 5, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Husson RN, Ross LA, Sandelli S, et al, &ldquo;Orally Administered Clarithromycin for the Treatment of Systemic <i>Mycobacterium avium</i> Complex Infection in Children With Acquired Immunodeficiency Syndrome,&rdquo; <i>J Pediatr</i>, 1994, 124(5 Pt 1):807-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8176574/pubmed\" target=\"_blank\" id=\"8176574\">8176574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jespersen CM, Als-Nielsen B, Damgaard M, et al, &ldquo;Randomised Placebo Controlled Multicentre Trial to Assess Short Term Clarithromycin for Patients with Stable Coronary Heart Disease: CLARICOR Trial,&rdquo; <i>BMJ</i>, 2006, 332(7532):22-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/16339220/pubmed\" target=\"_blank\" id=\"16339220\">16339220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koletzko S, Jones NL, Goodman KJ, et al. Evidence-Based Guidelines From ESPGHAN and NASPGHAN for <i>Helicobacter pylori</i> Infection in Children. <i>J Pediatr Gastroenterol Nutr</i>. 2011;53(2):230-243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/21558964/pubmed\" target=\"_blank\" id=\"21558964\">21558964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Langtry HD and Brogden RN, &ldquo;Clarithromycin. A Review of Its Efficacy in the Treatment of Respiratory Tract Infections in Immunocompetent Patients,&rdquo; <i>Drugs</i>, 1997, 53(6):973-1004.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/9179528/pubmed\" target=\"_blank\" id=\"9179528\">9179528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al. The Diagnosis and Management of Acute Otitis Media. <i>Pediatrics</i>. 2013;131(3):e964-999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. <i>Thorax</i>. 2009;64(Suppl 3:iii):1-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/19783532/pubmed\" target=\"_blank\" id=\"19783532\">19783532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. <i>CID</i>. 2007;44:S27-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McConnell SA and Amsden GW, &ldquo;Review and Comparison of Advanced-Generation Macrolides Clarithromycin and Dirithromycin,&rdquo; <i>Pharmacotherapy</i>, 1999, 19(4):404-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/10212011/pubmed\" target=\"_blank\" id=\"10212011\">10212011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi: 10.1038/ajg.2017.154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/28631728/pubmed\" target=\"_blank\" id=\"28631728\">28631728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nightingale SD, Koster FT, Mertz GJ, et al, &ldquo;Clarithromycin-Induced Mania in Two Patients With AIDS,&rdquo; <i>Clin Infect Dis</i>, 1995, 20(6):1563-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/7548513/pubmed\" target=\"_blank\" id=\"7548513\">7548513</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oteo JA, Gomez-Cadinanos RA, Rosel L, et al, &ldquo;Clarithromycin-Induced Thrombocytopenic Purpura,&rdquo; <i>Clin Infect Dis</i>, 1994, 19(6):1170-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/7888564/pubmed\" target=\"_blank\" id=\"7888564\">7888564</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peters DH and Clissold SP, &ldquo;Clarithromycin: A Review of its Antimicrobial Activity, Pharmacokinetic Properties, and Therapeutic Potential,&rdquo; <i>Drugs</i>, 1992, 44(1):117-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/1379907/pubmed\" target=\"_blank\" id=\"1379907\">1379907</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Pimozide (Orap) Contraindicated With Clarithromycin (Biaxin) and Other Macrolide Antibiotics,&rdquo; <i>FDA Medical Bulletin</i>, October 1996, 3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pollak PT, Sketris IS, MacKenzie SL, et al, &ldquo;Delirium Probably Induced by Clarithromycin in a Patient Receiving Fluoxetine,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(5):486-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/7655131/pubmed\" target=\"_blank\" id=\"7655131\">7655131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Service Task Force on Prophylaxis and Therapy for <i>Mycobacterium avium</i> Complex, &ldquo;Recommendations on Prophylaxis and Therapy for Disseminated <i>Mycobacterium avium</i> Complex Disease in Patients Infected With the Human Immunodeficiency Virus,&rdquo; <i>N Engl J Med</i>, 1993, 329(12):898-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8395019/pubmed\" target=\"_blank\" id=\"8395019\">8395019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sedlak T, Shufelt C, Iribarren C, et al, &quot;Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval,&quot; <i>Ann Noninvasive Electrocardiol</i>, 2013, 18(4):389-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/23879279/pubmed\" target=\"_blank\" id=\"23879279\">23879279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2012, 55(10):e86-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stafstrom CE, Nohria V, Loganbill H, et al, &ldquo;Erythromycin-induced Carbamazepine Toxicity: A Continuing Problem,&rdquo; <i>Arch Pediatr Adolesc Med</i>, 1995, 149(1):99-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/7827672/pubmed\" target=\"_blank\" id=\"7827672\">7827672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo; <i>Am J Gastroenterol</i>, 2005, 100(10):2324-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/16181387/pubmed\" target=\"_blank\" id=\"16181387\">16181387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tartaglione TA, &ldquo;Therapeutic Options for the Management and Prevention of <i>Mycobacterium avium</i> Complex Infection in Patients With the Acquired Immunodeficiency Syndrome,&rdquo; <i>Pharmacotherapy</i>, 1996, 16(2):171-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8820462/pubmed\" target=\"_blank\" id=\"8820462\">8820462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teare JP, Booth JC, Brown JL, et al, &ldquo;Pseudomembranous Colitis Following Clarithromycin Therapy,&rdquo; <i>Eur J Gastroenterol Hepatol</i>, 1995, 7(3):275-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/7743311/pubmed\" target=\"_blank\" id=\"7743311\">7743311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tiwari T, Murphy TV, and Moran J, &ldquo;Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines,&rdquo; <i>MMWR Recomm Rep</i>, 2005, 54(RR-14):1-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/16340941/pubmed\" target=\"_blank\" id=\"16340941\">16340941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace RJ Jr, Brown BA, and Griffith DE, &ldquo;Drug Intolerance to High-Dose Clarithromycin Among Elderly Patients,&rdquo; <i>Diagn Microbiol Infect Dis</i>, 1993, 16(3):215-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/8477575/pubmed\" target=\"_blank\" id=\"8477575\">8477575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; <i>Circulation</i>, 2007, 115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Witt A, Sommer EM, Cichna M, et al, &quot;Placental Passage of Clarithromycin Surpasses Other Macrolide Antibiotics,&quot; <i>Am J Obstet Gynecol</i>, 2003, 188(3):816-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/12634663/pubmed\" target=\"_blank\" id=\"12634663\">12634663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al. The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>, 2007;45(7):941]. <i>Clin Infect Dis</i>. 2006;43(9):1089-1134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, Bergman SA, Meiller TF, et al, &ldquo;Antibiotics in Treating Oral-Facial Infections of Odontogenic Origin: An Update,&rdquo; <i>Gen Dent</i>, 2001, 49(3):238-40, 242, 244 passim.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/12004720 /pubmed\" target=\"_blank\" id=\"12004720 \">12004720 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clarithromycin-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9273 Version 276.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F51130805\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F152372\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F152373\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F152420\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F152377\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F152399\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F152378\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F152379\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F152380\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F152345\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F152331\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F152349\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F152348\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F26122358\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F152427\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F152338\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F152352\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F152335\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F152413\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F152340\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F152368\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F152342\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F152355\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F152356\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6699915\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F152334\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F152351\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F152354\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F152358\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9273|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clarithromycin-patient-drug-information\" class=\"drug drug_patient\">Clarithromycin: Patient drug information</a></li><li><a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Clarithromycin: Pediatric drug information</a></li></ul></div></div>","javascript":null}